Yongqiang Wei - Department of Hematology Nanfang Hospital, Southern Medical University

基本信息

浏览量：43

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 182 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Efficacy and Safety of Third-Generation CD19-CAR T Cells Incorporating CD28 and TLR2 Intracellular Domains for B-cell Malignancies with Central Nervous System Involvement: Results of a Pivotal Trial

Bailin He,Ren Lin,Na Xu,Le Qin,Zhixiang Wang,Qiang Wang, Xiaofang Li,Xiaolei Wei,Yongqiang Wei, Zhaoyang Tang,Zhiping Fan,Fen Huang,Xiaoli Liu,Jing Sun,Li Xuan,Peng Li,Hongsheng Zhou,Qifa Liu

Journal of Translational Medicineno. 1 (2025): 1-12

引用0浏览0WOS引用

Weekly Selinexor, Bortizomib and Dexamethasone (svd) Versus Twice Weekly Bortizomib and Dexamethasone (vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Jin Lu, Liangquan Geng,Lijuan Chen,Peng Liu,Yuping Zhong,Zhuogang Liu,Zhongjun Xia,Jianqing Mi,Chunrui Li,Xi Zhang,Yanjuan He,Yongqiang Wei,Baijun Fang,Fei Li,Zhen Cai,Yafei Wang,Dongping Huang,Hong Liu,Ming Hou,Rong Fu,Xin Du,Xiaosheng Fang,Qingshu Zeng,Wen Gao, Wei Wang,Chunkang Chang,Guifang Ouyang,Jing Liu,Jianyu Weng,Xiaobing Huang, Yang Yu, Zhi Guo, Jun Zhao,Jian Hou

Bloodno. Supplement 1 (2024): 4748-4748

引用0浏览0引用

Metabolic Tumor Volume from Baseline [18 F]FDG PET/CT at Diagnosis Improves the IPI Stratification in Patients with Diffuse Large B-cell Lymphoma

Hanzhen Zhang, Zihan Xu,Wenlan Zhou, Junjie Chen,Yongqiang Wei,Hubing Wu,Xiaolei Wei,Ru Feng

ANNALS OF HEMATOLOGY (2024)

引用0浏览0WOS引用

Comparative Efficacy of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Vs. Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRD) in Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis

Yuqi Wang,Chen Huan, Zhang Hanzhen, Shanshan Zhang, Youhai Yuan,Ru Feng,Yongqiang Wei,Xiaolei Wei

BLOOD (2024): 7031-7031

引用0浏览0引用

Early Progression is Associated with Worse Survival in Patients with Waldenström’s Macroglobulinemia

Holistic Integrative Oncologyno. 1 (2024): 1-6

引用0浏览0引用

Optimizing Time-Limited Therapy in Unfit CLL/SLL Patients: Orelabrutinib, Bendamustine, and Obinutuzumab Combination (OBG) Regimen

Xutao Guo,Xiaolei Wei,Yongqiang Wei,Qi Wei,Ning Su, Yunxia Zhang, Haohao Lei,Ru Feng

Blood（2024）

引用0浏览0引用

Low Peripheral Blood B Lymphocyte Count Predict Poor Outcome in Patients with Multiple Myeloma

Yuqi Wang,Zhongxin Zheng, Qiaoxi Kang,Linjing Cai, Shanshan Zhang,Huan Chen, Youhai Yuan, Hanzhen Zhang,Xiaolei Wei,Ru Feng,Yongqiang Wei

crossref（2024）

引用0浏览0引用

Ultrasound Exhibited Superior Advantages over 18F-FDG PET/CT in Monitoring Follow-up of DLBCL

Zhang Hanzhen,Yongqiang Wei,Xiaolei Wei,Ru Feng

BLOOD (2024): 6456-6456

引用0浏览0引用

Sintilimab, Rituximab and Lenalidomide (sr2) As First-Line Treatment in Elderly Patients with Diffuse Large B-Cell Lymphoma: A Single-Arm, Open-Label, Phase 2 Trial

Xiaolei Wei,Xutao Guo,Qi Wei,Yongqiang Wei,Ru Feng

Bloodno. Supplement 1 (2024): 3121-3121

引用0浏览0引用

Inhibition of PKM2 Promotes Chemosensitivity of DOX in ABC-DLBCL Via Imbalance of Gsh/ROS and Inhibition of the NF-ΚB Pathway

Yutian Yang,Minglang Zhan, Zhang Hanzhen,Xiaolei Wei,Yongqiang Wei,Ru Feng

Bloodno. Supplement 1 (2024): 6244-6244

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn